乳香(Boswellia serrata)治疗脑转移瘤放射外科后脑放射性坏死
本研究纳入立体定向放射外科(SRS)后发生任何级别放射性坏死并接受乳香(BS)每日目标剂量4050至4500 mg、至少2个月的患者,94例随访充分者纳入分析。最佳疗效为完全缓解12%、部分缓解48%,总体客观缓解率(ORR)为59.6%(95% CI,48.9%-69.6%),中位缓解持续时间13.9个月(IQR,9-23)。作者认为BS对1至3级放射性坏死是安全可行的治疗选择,并认为需进一步开展与安慰剂对照的前瞻性研究。
要点
- BS治疗后总体ORR为59.6%(95% CI,48.9%-69.6%),1、2、3级放射性坏死ORR分别为62%、63%、33%。
- 最佳疗效为完全缓解12%、部分缓解48%,水肿稳定28%、进展12%。
- 14%患者出现1级胃肠道毒性,2%出现2级胃肠道毒性,67%患者在末次随访时仍在服用BS。
核心结论
- 作者认为,BS对SRS后1至3级放射性坏死是安全可行的治疗选择。
- 作者认为需进一步开展与安慰剂对照的前瞻性研究。
研究设计与样本
- 单系列病例评估,对象为脑转移瘤接受SRS后发生任何级别放射性坏死并接受BS至少2个月、每日目标剂量4050至4500 mg的患者。
- 共100例患者接受BS,其中94例随访充分者纳入分析。
- 中位SRS剂量为24 Gy分3次;1、2、3级放射性坏死的患者分别占44%、47%、9%。
主要发现
- 最佳疗效为完全缓解12%、部分缓解48%,水肿稳定28%、水肿进展12%。
- 总体ORR为59.6%(95% CI,48.9%-69.6%);1、2、3级放射性坏死的ORR分别为62%、63%、33%。
- 完全缓解或部分缓解患者的中位缓解持续时间为13.9个月(IQR,9-23)。
- 在从未使用类固醇、仅既往使用类固醇、或在开始BS前至少>1周地塞米松用量稳定或减少至≤4 mg/天的69例患者(73%)中,ORR为63.8%。
- 14%患者出现美国国家癌症研究所常见不良事件评价标准1级胃肠道毒性,2%出现2级胃肠道毒性;67%患者在末次随访时仍在服用BS。
关键数值与推荐
- 客观缓解率(ORR)包括完全缓解或部分缓解,部分缓解定义为T2液体衰减反转恢复磁共振成像上水肿体积较基线下降≥30%。
- BS目标剂量为每日4050至4500 mg,疗程≥2个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出需进一步开展与安慰剂对照的前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation necrosis (RN) is a dose-limiting toxicity of stereotactic radiosurgery (SRS) for brain metastases. Oral corticosteroids are not optimal for long-term management, given multiple side effects. Boswellia serrata (BS) is an over-the-counter supplement traditionally known for its anti-inflammatory properties and has recently been shown to reduce cerebral edema. We evaluated the response rates of BS in a series of patients with RN after SRS for brain metastases. METHODS AND MATERIALS: We identified patients who developed any grade RN after SRS and received BS for ≥2 months at a target dose of 4050 to 4500 mg daily. The primary endpoint was objective response rate (ORR), including complete response (CR) or partial response (PR), defined as ≥30% decrease in edema volume on T2-fluid-attenuated inversion recovery magnetic resonance imaging from baseline. RESULTS: A total of 100 patients received BS, of which 94 patients with adequate follow-up were included. The median SRS dose was 24 Gy in 3 fractions, and 44%, 47%, and 9% of patients had grade 1, 2, and 3 RN, respectively. The best response was CR in 12% and PR in 48%, while 28% had stable edema and 12% had progression of edema. The overall ORR was 59.6% (95% CI, 48.9%-69.6%). ORR was 62%, 63%, and 33% for grade 1, 2, and 3 RN, respectively. The median duration of response in patients with CR or PR was 13.9 months (IQR, 9-23). Among 69 patients (73%) who never received steroids, received prior steroids only, or had a stable or decreasing steroid requirement of ≤4 mg per day of dexamethasone for at least >1 week prior to starting Boswellia, the ORR was 63.8%. Fourteen percent of patients had National Cancer Institute Common Terminology Criteria for Adverse Events grade 1, and 2% had grade 2 gastrointestinal toxicity. A total of 67% of patients remained on BS at the last follow-up. CONCLUSIONS: Our study suggests that BS is a safe and feasible treatment option for grade 1 to 3 RN after SRS. Further prospective studies comparing BS with a placebo are warranted.
引用
- Upadhyay R, Elguindy ANM, Salts L, et al. Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2025. PMID: 39993542. doi:10.1016/j.ijrobp.2025.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。